| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2864000 | The American Journal of the Medical Sciences | 2013 | 7 Pages |
Abstract
TAC plus prednisone may be an alternative therapeutic option for steroid and general immunosuppressant-resistant membranous nephrotic syndrome patients, with a favorable safety profile. However, given the limitation of a small number of patients in this trial, further study with a larger number and longer follow-up is needed.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Wei MD, PhD, Qinghua MD, PhD, Yulian MD, Zhengrong MD, PhD, Xueqing MD, PhD, Yunhua MD, Zhenhua MD, Jian MD, PhD, Junzhou MD, PhD, Jinli MD, Yaozhong MD, Ping MD, PhD, Tanqi MD, PhD, Zhibin PhD,